2 days ago · Clinical biopharmaceutical company Eikon Therapeutics on Friday revealed wider nine-month losses in its filing for an initial public offering in the United States.

Eikon Therapeutics filed for an initial public offering. The late-stage clinical biopharmaceutical company didn't disclose in its Friday filing the price or amount of shares it would offer. It ...

2 days ago · Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs.

All the information you need to install and to download Refinitiv Eikon. Direct link to test if your system can run Refinitiv Eikon.

2 days ago · Eikon Therapeutics filed for a Nasdaq IPO after raising $1.1 billion for cancer drugs, led by ex-Amgen and Merck exec Roger Perlmutter.

Eikon TherapeuticsPrint

Eikon Therapeutics is a late-stage clinical biopharmaceutical firm developing innovative medicines for serious unmet medical needs, with an initial focus on oncology.

Feb 26, 2025 · Since its founding in 2019, Eikon Therapeutics has privately raised in excess of $1.1 billion to support its mission of developing new medicines to address grievous illnesses.

Feb 26, 2025 · Eikon was formed around a Nobel Prize-winning technology that helps scientists look at how proteins move inside of cells. The company debuted publicly in 2021 with Roger Perlmutter, …

Feb 26, 2025 · Eikon Therapeutics’ lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also...